Investor Relations

SEC Filings

  o View CEL-SCI's SEC Filings  
       

Corporate Overview

  o View Corporate Overview  
       

CEL-SCI Presentations & Interviews

  April 10, 2018
Geert Kersten's Presentation from The Microcap Conference

 
  February 13, 2018
Geert Kersten at the 2018 BIO CEO & Investor Conference

 
  September 11, 2017
Geert Kersten at the Rodman & Renshaw 19th Annual Global Investment Conference

 
  February 2016
Geert Kersten as a featured guest on Fox Business' Making Money with Charles Payne

 
  January 2016
Interview with Dr. Eyal Talor, Chief Scientific Officer

 
  January 2016
Geert Kersten at the Noble Financial Capital Markets' 12th Annual Investor Conference

 

Warrant Quote

  o NYSE American: CVM WS  

 

Press Releases

  o All Press Releases  
 
  APRIL 4, 2018
NEW STORY CEL-SCI Issues Letter to Shareholders
  APRIL 3, 2018
NEW STORY CEL-SCI Announces Adjustment to Warrant Exercise Price
  FEBRUARY 23, 2018
NEW STORY CEL-SCI Extends the Expiration Date of Series DD and Series EE Warrants Issued In December 2016
  FEBRUARY 12, 2018
NEW STORY CEL-SCI Corporation Reports First Quarter Fiscal 2018 Financial Results
  JANUARY 30, 2018
NEW STORY U.S. Patent Office Allows New CEL-SCI Patent For LEAPS Vaccine Platform Technology
  JANUARY 8, 2018
NEW STORY CEL-SCI Awarded Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis
  DECEMBER 29, 2017
NEW STORY CEL-SCI Reports Fiscal 2017 Financial Results and Clinical & Corporate Developments
  DECEMBER 18, 2017
NEW STORY CEL-SCI Announces Robert Watson Joins Its Board of Directors
  DECEMBER 11, 2017
NEW STORY CEL-SCI Reaches Full Enrollment in Pivotal Phase 3 Head and Neck Cancer Study
  DECEMBER 7, 2017
NEW STORY CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study
  NOVEMBER 13, 2017
NEW STORY CEL-SCI Announces Update on Arbitration against Former Clinical Research Organization
  OCTOBER 10, 2017
NEW STORY CEL-SCI Granted European Patent for Multikine's Mechanism of Action in Making Tumors 'Visible' To the Immune System
  SEPTEMBER 19, 2017
NEW STORY CEL-SCI Announces $1.5 Million NIH SBIR Grant to Support Development of Rheumatoid Arthritis Vaccine
  AUGUST 14, 2017
NEW STORY U.S. FDA Removes Clinical Hold on CEL-SCI's Phase 3 Head & Neck Cancer Trial
  JUNE 12, 2017
NEW STORY CEL-SCI Announces Reverse Stock Split
  JUNE 8, 2017
NEW STORY CEL-SCI Announces New Data for Its Rheumatoid Arthritis Vaccine Candidate Published in Peer Reviewed Journal

Investor Relations Contact

   

Gavin de Windt
Phone: +1 703-506-9460
E-mail: gdewindt@cel-sci.com